Enhanced therapeutic effects for human pancreatic cancer by application K-ras and IGF-IR antisense oligodeoxynucleotides

World Journal of Gastroenterology

Volumn 14, Issue 33, 2008, Pages 5176-5185

  Shen, Yong Mei ^a   Yang, Xiao Chun ^a   Yang, Chen ^b   Shen, Jun Kang ^a  

^a SOOCHOW UNIVERSITY   (China)

^b Suzhou Municipal Hospital   (China)

Author keywords

Antisense oligodeoxynucleotide; K ras; Pancreatic cancer; Patu8988; Type I insulin like growth factor receptor

Indexed keywords

ANTINEOPLASTIC AGENT; ANTISENSE OLIGODEOXYNUCLEOTIDE; INSULIN LIKE GROWTH FACTOR RECEPTOR 1 ANTISENSE OLIGODEOXYNUCLEOTIDE; K RAS ANTISENSE OLIGODEOXYNUCLEOTIDE; K RAS PROTEIN; MESSENGER RNA; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; SOMATOMEDIN C; UNCLASSIFIED DRUG; PROTEIN P21; SOMATOMEDIN C RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BAGG ALBINO MOUSE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CELL PROLIFERATION; CELL STRUCTURE; CODON; COLONY FORMING UNIT; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENTIATION; DRUG PROTEIN BINDING; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PANCREAS CANCER; POINT MUTATION; POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TRANSMISSION ELECTRON MICROSCOPY; ADENOCARCINOMA; ANIMAL; DRUG EFFECT; GENETICS; METABOLISM; NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; OLIGODEOXYRIBONUCLEOTIDES, ANTISENSE; PANCREATIC NEOPLASMS; POINT MUTATION; PROTO-ONCOGENE PROTEINS P21(RAS); RECEPTOR, IGF TYPE 1; RNA, MESSENGER;

EID: 58149241090     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.14.5176     Document Type: Article

References (27)

1. Nitecki SS, Sarr MG, Colby TV, van Heerden JA. Long-term survival after resection for ductal adenocarcinoma of the pancreas. Is it really improving? Ann Surg 1995; 221: 59-66
2. Coppola D. Molecular prognostic markers in pancreatic cancer. Cancer Control 2000; 7: 421-427
3. Welsch T, Kleeff J, Friess H. Molecular pathogenesis of pancreatic cancer: advances and challenges. Curr Mol Med 2007; 7: 504-521
4. Boeck S, Heinemann V. The role of second-line chemotherapy after gemcitabine failure in patients with advanced pancreatic cancer. Future Oncol 2008; 4: 41-50
5. Brasiuniene B, Juozaityte E. The effect of combined treatment methods on survival and toxicity in patients with pancreatic cancer. Medicina (Kaunas) 2007; 43: 716-725
6. Plate JM. Current immunotherapeutic strategies in pancreatic cancer. Surg Oncol Clin N Am 2007; 16: 919-943, xi
7. Deramaudt T, Rustgi AK. Mutant KRAS in the initiation of pancreatic cancer. Biochim Biophys Acta 2005; 1756: 97-101
8. Fryzek JP, Garabrant DH, Schenk M, Kinnard M, Greenson JK, Sarkar FH. The Association Between Selected Risk Factors for Pancreatic Cancer and the Expression of p53 and K-ras Codon 12 Mutations. Int J Gastrointest Cancer 2006; 37: 139-145
9. Jiao L, Zhu J, Hassan MM, Evans DB, Abbruzzese JL, Li D. K-ras mutation and p16 and preproenkephalin promoter hypermethylation in plasma DNA of pancreatic cancer patients: in relation to cigarette smoking. Pancreas 2007; 34: 55-62
10. Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT, Nadaf S, Carbone DP, Imai K. Genetic blockade of the insulin-like growth factor-I receptor: a promising strategy for human pancreatic cancer. Cancer Res 2003; 63: 6432-6441
11. Liu W, Bloom DA, Cance WG, Kurenova EV, Golubovskaya VM, Hochwald SN. FAK and IGF-IR interact to provide survival signals in human pancreatic adenocarcinoma cells. Carcinogenesis 2008; 29: 1096-1107
12. Wang YX, Gao L, Ji ZZ. Inhibitary effects of antisense oligonucleotide specific to K-ras point mutation on the target gene expression in human pancreatic carcinoma cells. Chin Med J (Engl) 2007; 120: 1448-1450
13. Zhou NX, Fen YQ, Huang ZQ, Wang YZ, Xu QS. Growth inhibition of pancreatic cancer by antisense oligonucleotide against the insulin-like factor-I receptor. Zhonghua Putong Waike Zazhi 1999; 29: 247-251
14. Masui T, Hosotani R, Ito D, Kami K, Koizumi M, Mori T, Toyoda E, Nakajima S, Miyamoto Y, Fujimoto K, Doi R. Bcl-XL antisense oligonucleotides coupled with antennapedia enhances radiation-induced apoptosis in pancreatic cancer. Surgery 2006; 140: 149-160
15. Hotz HG, Hines OJ, Masood R, Hotz B, Foitzik T, Buhr HJ, Gill PS, Reber HA. VEGF antisense therapy inhibits tumor growth and improves survival in experimental pancreatic cancer. Surgery 2005; 137: 192-199
16. Resnicoff M, Coppola D, Sell C, Rubin R, Ferrone S, Baserga R. Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res 1994; 54: 4848-4850
17. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Perucho M. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 1988; 53: 549-554
18. Berndt C, Haubold K, Wenger F, Brux B, Muller J, Bendzko P, Hillebrand T, Kottgen E, Zanow J. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem 1998; 44: 2103-2107
19. Fleming JB, Shen GL, Holloway SE, Davis M, Brekken RA. Molecular consequences of silencing mutant K-ras in pancreatic cancer cells: justification for K-ras-directed therapy. Mol Cancer Res 2005; 3: 413-423
20. Zhu H, Liang ZY, Ren XY, Liu TH. Small interfering RNAs targeting mutant K-ras inhibit human pancreatic carcinoma cells growth in vitro and in vivo. Cancer Biol Ther 2006; 5: 1693-1698
21. Wang YX, Gao L, Ji ZZ. [The study of the effect of antisense oligonucleotide specific to K-ras point mutation on human pancreatic carcinoma cell PC-2] Zhonghua Waike Zazhi 2005; 43: 1387-1390
22. Nakada Y, Saito S, Ohzawa K, Morioka CY, Kita K, Minemura M, Takahara T, Watanabe A. Antisense oligonucleotides specific to mutated K-ras genes inhibit invasiveness of human pancreatic cancer cell lines. Pancreatology 2001; 1: 314-319
23. Su Z, Lebedeva IV, Gopalkrishnan RV, Goldstein NI, Stein CA, Reed JC, Dent P, Fisher PB. A combinatorial approach for selectively inducing programmed cell death in human pancreatic cancer cells. Proc Natl Acad Sci USA 2001; 98: 10332-10337
24. Lebedeva IV, Su ZZ, Emdad L, Kolomeyer A, Sarkar D, Kitada S, Waxman S, Reed JC, Fisher PB. Targeting inhibition of K-ras enhances Ad.mda-7-induced growth suppression and apoptosis in mutant K-ras colorectal cancer cells. Oncogene 2007; 26: 733-744
25. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM, Blattler WA, Chittenden T, Singh R. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083
26. Pan YZ, Sun CY, Wang YZ. The growth inhibition of human pancreatic cancer cells by lipofectin mediated IGF-1R antisense oligonucleotides. Zhonghua Heyixue Zazhi; 2005; 25: 212-215
27. Adachi Y, Lee CT, Carbone DP. Genetic blockade of the insulin-like growth factor 1 receptor for human malignancy. Novartis Found Symp 2004; 262: 177-189; discussion 190-192, 265-268